Immune checkpoint inhibitors (ICI), including the programmed death protein 1 (PD-1, pembrolizumab, nivolumab) and cytotoxic T lymphocyte associated protein 4 (CTLA-4, ipilimumab), recently turned out to be effective in melanoma treatment. This evidence concerns the gene CTLA4 and melanoma.